Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer
Introduction Tumor angiogenesis is regulated by numerous cytokines and growth factors, with vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 2 (sVEGFR-2), and galectin-3, playing a significant role in the process. There are conflicting data concerning changes in serum VEGF, sVEGFR-2 and galectin-3 levels in breast cancer (BC) patients during the course of the disease and chemotherapy (CTH). This study aimed to assess the serum levels of VEGF-A, sVEGFR-2, and galectin-3 in women starting adjuvant and neoadjuvant therapy for BC, and their changes during the treatment. Material and methods This single-center study enrolled 98 women with non-metastatic BC, including 56 who started adjuvant therapy and 42 preoperative (neoadjuvant/induction) CTH. The serum levels of VEGF-A, sVEGFR-2, and galectin-3 were assessed at the beginning of CTH and after 2 subsequent months. Results There were no significant differences in the serum levels of VEGF-A, sVEGFR-2, and galectin-3 between patients starting adjuvant and preoperative therapy. In addition, there was no correlation between the serum levels and the clinical stage of BC. During CTH, a significant increase in VEGF-A, sVEGFR-2, and galectin-3 was noted, however, without a predictive significance for obtaining complete pathological response (pCR) both for the initial levels and changes in the serum levels. Conclusions The serum levels of VEGF-A, sVEGFR-2, and galectin-3 do not correlate with the clinical stage or tumor size in patients with non-metastatic BC. The baseline levels of VEGF-A, sVEGFR-2 and galectin-3, and the observed increase in the serum levels of VEGF-A and sVEGFR-2 during CTH do not predict its efficacy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Annales Academiae Medicae Silesiensis - 76(2022), Seite 96-105 |
| Sprache: |
Englisch ; Polnisch |
|---|
| Beteiligte Personen: |
Iga Grochoła-Małecka [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Angiogenesis |
|---|
| doi: |
10.18794/aams/149208 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ004545656 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ004545656 | ||
| 003 | DE-627 | ||
| 005 | 20230311014055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18794/aams/149208 |2 doi | |
| 035 | |a (DE-627)DOAJ004545656 | ||
| 035 | |a (DE-599)DOAJf16b7a233ef34adea77e883992db8bd1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a pol | ||
| 050 | 0 | |a RS1-441 | |
| 050 | 0 | |a RK1-715 | |
| 100 | 0 | |a Iga Grochoła-Małecka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction Tumor angiogenesis is regulated by numerous cytokines and growth factors, with vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 2 (sVEGFR-2), and galectin-3, playing a significant role in the process. There are conflicting data concerning changes in serum VEGF, sVEGFR-2 and galectin-3 levels in breast cancer (BC) patients during the course of the disease and chemotherapy (CTH). This study aimed to assess the serum levels of VEGF-A, sVEGFR-2, and galectin-3 in women starting adjuvant and neoadjuvant therapy for BC, and their changes during the treatment. Material and methods This single-center study enrolled 98 women with non-metastatic BC, including 56 who started adjuvant therapy and 42 preoperative (neoadjuvant/induction) CTH. The serum levels of VEGF-A, sVEGFR-2, and galectin-3 were assessed at the beginning of CTH and after 2 subsequent months. Results There were no significant differences in the serum levels of VEGF-A, sVEGFR-2, and galectin-3 between patients starting adjuvant and preoperative therapy. In addition, there was no correlation between the serum levels and the clinical stage of BC. During CTH, a significant increase in VEGF-A, sVEGFR-2, and galectin-3 was noted, however, without a predictive significance for obtaining complete pathological response (pCR) both for the initial levels and changes in the serum levels. Conclusions The serum levels of VEGF-A, sVEGFR-2, and galectin-3 do not correlate with the clinical stage or tumor size in patients with non-metastatic BC. The baseline levels of VEGF-A, sVEGFR-2 and galectin-3, and the observed increase in the serum levels of VEGF-A and sVEGFR-2 during CTH do not predict its efficacy. | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a angiogenesis | |
| 650 | 4 | |a galectin-3 | |
| 650 | 4 | |a vascular endothelial growth factor | |
| 650 | 4 | |a chemotherapy | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 653 | 0 | |a Dentistry | |
| 700 | 0 | |a Paulina Czajka-Francuz |e verfasserin |4 aut | |
| 700 | 0 | |a Aleksander Jerzy Owczarek |e verfasserin |4 aut | |
| 700 | 0 | |a Jerzy Wojnar |e verfasserin |4 aut | |
| 700 | 0 | |a Gabriela Handzlik |e verfasserin |4 aut | |
| 700 | 0 | |a Tomasz Francuz |e verfasserin |4 aut | |
| 700 | 0 | |a Jerzy Chudek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Annales Academiae Medicae Silesiensis |d Śląski Uniwersytet Medyczny w Katowicach, 2022 |g 76(2022), Seite 96-105 |w (DE-627)DOAJ000149640 |x 1734025X |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2022 |g pages:96-105 |
| 856 | 4 | 0 | |u https://doi.org/10.18794/aams/149208 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f16b7a233ef34adea77e883992db8bd1 |z kostenfrei |
| 856 | 4 | 0 | |u https://annales.sum.edu.pl/Serum-levels-of-VEGF-A-sVEGFR-2-and-galectin-3-do-not-correlate-with-clinical-stage,149208,0,2.html |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1734-025X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2022 |h 96-105 | ||